|
Abstract: Nucleos(t)ide analogues (NAs) are the main agents in anti-HBV therapy. NAs are potent in
inhibiting HBV replication and have good safety profiles. With more and more patients are taking NAs, case
reports about the side effects on kidney, bone, muscle and neurological are also increasing. The incidences
of these side effects are very low, but they may cause severe consequences. To optimize the management of
NAs related side effects, we drafted the experts’ consensus on management of side effects of nucleos(t)ide
analogues for hepatitis B virus.
|